{'fraction_non_alphanumeric': 0.037283621837549935, 'fraction_numerical': 0.02463382157123835, 'mean_word_length': 5.5064935064935066, 'pattern_counts': {'":': 0, '<': 1, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Effect of atorvastatin and rosuvastatin on 25-hydroxy vitamin d levels in newly diagnosed South Indian dyslipidemic subjects

Background: Statins are one of the mainstay treatment modality for the people suffering from dyslipidemia. Statins reduce the cholesterol bio-synthesis by ß-hydroxy-ß-methyl glutaryl Co-A (HMG-CoA) reductase inhibition which is rate-limiting enzyme. It also affects the Vit-D levels as metabolism of cholecalciferol and cholesterol are interrelated. Objectives: Effect of atorvastatin/ rosuvastatin on 25-hydroxy Vitamin-D (25OHD) concentrations among subjects with newly diagnosed dyslipidemia. Materials and Methods: Prospective randomized, open-label, parallel group study. Lipid and 25OHD levels are measured at baseline and end of 6 months after statin treatment. One group received atorvastatin and another study group received rosuvastatin for 6 months. Results: Mean 25OHD concentrations are 32.0±4.7, 31.7±4.8 and 32.9±4.9 in the control, atorvastatin and rosuvastatin groups respectively. Both atorvastatin and rosuvastatin groups, except TGs, all the lipid parameters and 25OHD has showed significant difference (<0.001) from baseline to end-line repeated parameters. All the study participants were well tolerated and no one discontinued the drug due to drug-related adverse reactions. Conclusion: Participants with atorvastatin treated group showed significant reduction in 25OHD concentrations. In addition, 25OHD concentrations are dependent on statin efficacy.